Alzinova AB (publ) (STO:ALZ)

Market Cap	61.13M -77.4%
Revenue (ttm)	26.12M +50.1%
Net Income	-26.94M
EPS	-0.29
Shares Out	104.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	214,136
Average Volume	503,070
Open	0.5890
Previous Close	0.5860
Day's Range	0.5840 - 0.6200
52-Week Range	0.5700 - 3.8200
Beta	1.39
RSI	22.95
Earnings Date	Feb 26, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s d...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ALZ

Financial Performance

In 2024, Alzinova AB's revenue was 16.81 million, a decrease of -15.41% compared to the previous year's 19.87 million. Losses were -20.55 million, 24.7% more than in 2023.